- 20% of patients infected with MRSA are dying from systemic infections
- Antimicrobial resistance infections are projected to cause more deaths than cancer by 2050 if not addressed urgently.
Tuesday, 15 Nov., 2016: Microbiologists have identified how MRSA may be more effectively treated by modern-day antibiotics, if old-fashioned penicillin is also used. The team from the National University of Ireland Galway and the University of Liverpool have shown that, although penicillin does not kill the bacteria, it does weaken their virulence, making it easier for our immune system and other antibiotics to eradicate the infection. The research findings, funded by the Health Research Board and the Medical Research Council, are published today (15 November 2016) in the Journal of Infectious Diseases.
MRSA infection is caused by a type of Staphylococcal bacteria that has become resistant to many of the antibiotics used to treat ordinary infections. This results in significant morbidity and mortality with up to 20% of patients infected with MRSA dying from systemic infections.
Professor James O'Gara of the National University of Ireland Galway comments: "Our findings explain the anti-virulence mechanism of penicillin-type antibiotics and support the re-introduction of these drugs as an adjunct therapeutic for MRSA infections. MRSA can be extremely virulent, which is part of the challenge in treating it. Our laboratory research shows that when exposed to penicillin, the bacteria switches off its toxin genes and instead concentrates on thickening its cell wall to resist the antibiotic. Our immune systems can then take advantage of this compromised state to destroy the bacteria."
This new treatment strategy for MRSA infections has the potential to change the current clinical guidelines for treatment of patients with MRSA infections in both hospital and community settings. A recent randomised controlled trial in Australia involving 60 patients led by Menzies School of Health Research showed that the beta-lactam antibiotic flucloxacillin in combination with vancomycin significantly reduced the duration of MRSA sepsis from 3 days to 1.9 days.
"The clinical findings in Australia are very important and now we have the key laboratory data that help explain why the combination of two antibiotics is better than one. The beauty of this approach is that penicillin type antibiotics are not only widely available and safe, but can potentially and more easily be included in clinical practice without the need for long and expensive clinical trials needed for new drugs," added Professor O'Gara.
Graham Love, Chief Executive at the Health Research Board commented: "This research demonstrates the potential payback having a vibrant health research programme. It clearly has the potential to change clinical practice and improve outcomes for patients."
Antimicrobial resistance (AMR) is one of the greatest current threats to human health. The recent report commissioned by the UK Government, concluding that AMR infections will cause more deaths than cancer by 2050 if not addressed urgently.
Study co-lead Professor Aras Kadioglu at the Institute of Infection & Global Health, University of Liverpool added that: "Although aggressive hospital infection control initiatives appear to be having a positive impact on hospital-acquired MRSA rates in some developed countries, the global burden still remains unacceptably high. Infections caused by community associated MRSA strains and strains that are currently methicillin sensitive are increasing at a worrying speed. Given the escalating antimicrobial resistance crisis, it is imperative to identify new therapeutic strategies and to re-evaluate how current antimicrobial drugs are used, as such our data are timely and highly important."
Image caption: New research shows that the virulence of MRSA can be weakened using old-fashioned penicillin, allowing the immune system a better chance to eradicate the infection. The new research is published today by a team from the National University of Ireland Galway and the University of Liverpool in the Journal of Infectious Diseases. Image courtesy NUI Galway. REPRO FREE.
For further information contact Ruth Hynes, Press and Information Executive, NUI Galway on 091 495695 or firstname.lastname@example.org
About NUI Galway
The University was established in the heart of Galway City, on the west coast of Ireland, in 1845. Since then it has advanced knowledge teaching and learning, through research and innovation, and community engagement.
Over 18,000 students study at NUI Galway, where 2,600 staff provide the very best in research-led education.
NUI Galway's teaching and research is recognised through its consistent rise in international rankings. The University is placed in the Top 250 of both the Times Higher Education (THE) World University Rankings 2016/2017 and the QS World University Rankings 2016/17.
With an extensive network of industry, community and academic collaborators around the world, NUI Galway researchers are tackling some of the most pressing issues of our times. Internationally renowned research centres based here include The National Centre for Biomedical Engineering and Science, CÚRAM Centre for Research in Medical Devices, Insight Centre for Data Analytics, Moore Institute, Institute for Life Course and Society and The Ryan Institute for Environmental, Marine and Energy.
NUI Galway has been listed as one of the most beautiful universities in Europe according to Business Insider. For more information visit http://www.
*The University's official title is National University of Ireland Galway. Please note that the only official abbreviation is NUI Galway.
The University of Liverpool
The University of Liverpool is one of the UK's leading research institutions with an annual turnover of £465 million, including £89 million for research. Liverpool is ranked in the top 1% of higher education institutions worldwide and is a member of the Russell Group. Visit http://www.